| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | 4-[(1R)-2-[6-[2-[(2,6-Dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol | FAERS: 1 | US FAERS | |
| 2 | Erlotinib Hydrochloride | FAERS: 1 | US FAERS | |
| 3 | Fingolimod Hydrochloride | FAERS: 1 | US FAERS | |
| 4 | Gefitinib | FAERS: 1 | US FAERS | |
| 5 | Oxycodone and acetaminophen | FAERS: 1 | US FAERS | |
| 6 | fluticasone furoate | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120267
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.